Endometrial Cancer

Understanding Endometrial Cancer: Symptoms, Diagnosis, Treatment, and Life After Diagnosis

Endometrial cancer starts in the lining of the uterus, called the endometrium. For many people, the first sign is unusual bleeding, which means the disease is often found early. This guide explains what endometrial cancer is, what raises the risk, how doctors diagnose and stage it, which treatments are used today, and what patients and families should know while making decisions.

What is Endometrial Cancer?

Endometrial cancer is a cancer that begins in the inner lining of the uterus. It is different from the rarer cancers that start in the muscle of the uterus, called uterine sarcomas. In most cases, it develops after changes in the endometrial cells build up over time (National Cancer Institute, 2025a).

The uterus has an outer muscular wall and an inner lining that thickens and sheds during the menstrual cycle. Endometrial cancer begins when some of the cells in that lining grow out of control. Many cases are endometrioid cancers, which are often linked to hormone related pathways and may behave less aggressively than some non endometrioid subtypes such as serous or clear cell cancers (Concin et al., 2021; Galant et al., 2024).

Doctors now look at endometrial cancer in two ways. The first is what the cancer looks like under the microscope. The second is its molecular profile, which studies the tumor's genetic and protein signals. Tumors can fall into POLE mutated, mismatch repair deficient, p53 abnormal, or no specific molecular profile groups, and these groups can carry very different risks (Berek et al., 2023; Galant et al., 2024).

If you have just been told you may have endometrial cancer, it is normal to feel frightened. Try to remember that this is one of the gynecologic cancers that is often found at a stage where treatment can work very well.

How common is Endometrial Cancer?

Endometrial cancer is common, and its burden is rising in many parts of the world. Globally, the International Agency for Research on Cancer estimated 420,368 new corpus uteri cancers and 97,723 deaths in 2022. The United States National Cancer Institute estimated 69,120 new uterine corpus cancers and 13,860 deaths in 2025, and most of these cancers arise in the endometrium (International Agency for Research on Cancer, 2024; National Cancer Institute, 2025a).

The disease is more common in higher income regions, especially North America and Europe, and it is usually diagnosed after menopause. Aging populations, obesity, diabetes, and other metabolic conditions are major reasons the number of cases has been increasing (International Agency for Research on Cancer, 2024; Galant et al., 2024).

Younger people can also develop it, especially with strong hormonal or inherited risk factors. So age should never be used to dismiss abnormal bleeding.

What causes Endometrial Cancer?

There is no single cause of endometrial cancer, but the best established pattern is long term exposure to estrogen without enough balancing progesterone. This hormonal environment can stimulate the lining of the uterus, cause overgrowth, and in some people lead from hyperplasia to cancer over time (National Cancer Institute, 2025a).

Risk factors that can increase the chance of endometrial cancer include:

• Obesity and weight gain in adult life

• Metabolic syndrome and type 2 diabetes

• Polycystic ovary syndrome

• Never having given birth

• Starting periods early or reaching menopause later

• Estrogen only hormone therapy after menopause

• Tamoxifen use for breast cancer

• Endometrial hyperplasia

• A first degree relative with endometrial cancer

• Lynch syndrome and some other inherited cancer syndromes

• Older age (National Cancer Institute, 2025a)

These risk factors do not mean a person will definitely get cancer. They simply change the odds. Many people with risk factors never develop endometrial cancer, and some people who are diagnosed have no obvious risk factor at all.

At a biology level, some tumors grow in a hormone driven setting, while others are shaped by mismatch repair defects, p53 abnormalities, or other molecular changes. This is one reason two patients with the same stage can still have different treatment plans and different outlooks (Galant et al., 2024).

What are the symptoms of Endometrial Cancer?

The most important symptom of endometrial cancer is abnormal vaginal bleeding. That can mean bleeding after menopause, bleeding between periods, or periods that become much heavier or more prolonged than usual. Pelvic pain, unusual discharge, pain during sex, or urinary discomfort can also happen, but bleeding is the symptom doctors take most seriously (National Cancer Institute, 2025a).

Symptoms that deserve prompt medical attention include:

• Bleeding or spotting after menopause

• Bleeding between periods

• Heavier, longer, or more irregular periods than usual

• Vaginal discharge that is new or unusual

• Pelvic pain or pressure

• Pain during sex

• Difficult or painful urination (National Cancer Institute, 2025a)

Many of these symptoms can be caused by non cancer conditions such as fibroids, polyps, hormonal changes, or infection. Even so, new bleeding should never be ignored, especially after menopause.

How is Endometrial Cancer diagnosed?

Doctors diagnose endometrial cancer by taking a sample of tissue from the lining of the uterus and examining it under a microscope. Ultrasound can help point to a problem, but tissue is needed to confirm the diagnosis. After cancer is confirmed, imaging and pathology results are used to work out the stage and risk category (National Cancer Institute, 2025a; Berek et al., 2023).

In practice, diagnosis happens step by step. A doctor asks about bleeding, menopause status, tamoxifen use, and family history. A transvaginal ultrasound is often one of the first tests, but it cannot prove cancer. For that, doctors need tissue (National Cancer Institute, 2025a).

The key test is an endometrial biopsy. Sometimes hysteroscopy or dilation and curettage is needed, especially if the biopsy is unclear or a focal lesion is suspected (National Cancer Institute, 2025a).

Once cancer is confirmed, MRI or CT may help assess depth of invasion and spread. Final stage is often confirmed after surgery and pathology review. The updated FIGO system includes where the cancer has spread plus key histologic and molecular information that can refine prognosis and treatment planning (Berek et al., 2023).

A Pap test usually cannot rule out endometrial cancer because it is mainly designed for cervical screening (National Cancer Institute, 2025a).

Is there routine screening for Endometrial Cancer?

For people at average risk and without symptoms, there is no standard routine screening test that has been shown to reduce deaths from endometrial cancer. Instead, early detection usually depends on recognizing symptoms quickly and getting evaluated without delay (National Cancer Institute, 2025b).

If you have unexpected bleeding, especially after menopause, it is more useful to get timely medical review than to wait for a screening program that does not exist for the general population.

How is Endometrial Cancer treated?

Treatment for endometrial cancer depends on stage, grade, histologic subtype, molecular profile, whether the cancer is newly diagnosed or recurrent, and the patient's overall health and goals. Surgery is the main treatment for many early cancers, while radiation, chemotherapy, hormone treatment, immunotherapy, or combinations of these may be added when risk is higher or the disease has spread (Concin et al., 2021; National Cancer Institute, 2025a).

Surgery

Surgery is the backbone of treatment for most people with newly diagnosed endometrial cancer. The standard operation usually involves removal of the uterus, both fallopian tubes, and both ovaries. Depending on the case, surgeons may also assess lymph nodes, often with a sentinel node approach in selected patients (Concin et al., 2021; National Cancer Institute, 2025a).

Many operations can be done using minimally invasive techniques, which can mean less pain and quicker recovery. Surgery also gives the most accurate information about stage, depth of invasion, and lymph node involvement (Concin et al., 2021).

Radiation therapy

Radiation is often used after surgery when there is a meaningful risk of the cancer coming back in the pelvis or vagina. Some people receive vaginal brachytherapy, which treats the upper vagina locally. Others need external beam radiation, especially when disease is more extensive or the recurrence risk is higher (Concin et al., 2021; National Cancer Institute, 2025a).

When surgery is not possible, radiation can also be part of the main treatment plan. In recurrent disease, it may sometimes help control local symptoms or treat a limited relapse.

Chemotherapy

Chemotherapy is commonly used for higher risk disease, stage III or IV disease, or cancer that has come back. A standard combination is carboplatin plus paclitaxel. The goal may be to reduce the chance of recurrence after surgery, shrink active disease, or slow disease that has spread (National Cancer Institute, 2025a; Concin et al., 2021).

Common side effects can include fatigue, nausea, hair loss, low blood counts, numbness or tingling in hands and feet, and higher infection risk. Supportive medicines can help a great deal.

Hormone therapy and fertility preserving care

Hormone treatment can be useful for selected tumors, especially slower growing cancers that are hormone receptor positive. Progestin based treatment may be considered for some recurrent cases or for patients who are not good candidates for surgery or radiation (National Cancer Institute, 2025a).

For a small and carefully selected group with very early, low grade endometrioid cancer who strongly wish to preserve fertility, uterus sparing treatment may be discussed in expert centers. This is not the standard treatment, and it requires strict selection, close follow up, and honest discussion about risks and timing (Rodolakis et al., 2023).

Immunotherapy and targeted treatment

Molecular testing can show whether a tumor is mismatch repair deficient or has other features that make immunotherapy more likely to help. These results now matter clinically, not just academically (Galant et al., 2024).

In advanced or recurrent disease, adding pembrolizumab to carboplatin and paclitaxel improved progression free survival compared with chemotherapy alone in the NRG GY018 trial. In the RUBY trial, dostarlimab plus carboplatin and paclitaxel also improved progression free survival, with especially strong benefit in mismatch repair deficient or MSI high disease (Eskander et al., 2023; Mirza et al., 2023).

These treatments can be very helpful, but they also bring distinct side effects. Because they stimulate the immune system, they can inflame normal organs, including the thyroid, colon, liver, lungs, or skin. That is why patients need close follow up and fast reporting of new symptoms.

What is the outlook for people with Endometrial Cancer?

The outlook for endometrial cancer is often good when the disease is found early, but prognosis varies widely. Stage, grade, histologic subtype, lymph node involvement, molecular profile, and overall health all matter. In broad SEER based estimates, the five year relative survival is about 96% for localized disease, 72% for regional disease, and 22% for distant disease (American Cancer Society, 2025).

It is important to read survival numbers carefully. They describe groups, not individuals. They also reflect people treated over several past years, so they may not fully capture the benefit of newer approaches such as modern molecular risk grouping and immunotherapy.

Certain tumor types, such as p53 abnormal and some serous cancers, can behave more aggressively. By contrast, POLE mutated tumors often have a more favorable outlook. This is why molecular classification is becoming part of real world treatment planning and not just research (Berek et al., 2023; Galant et al., 2024).

Outlook is also shaped by when a patient reaches specialist care. Fast assessment of bleeding, accurate pathology, appropriate surgery, and timely access to additional treatment can all influence outcomes in a meaningful way.

Living with Endometrial Cancer: Practical Tips for Patients and Families

Living with endometrial cancer is about more than getting through treatment. It is also about preserving strength, mood, relationships, sleep, sexual health, and confidence during a period that can feel very uncertain. Small practical steps often make the process more manageable.

Try to keep a written record of symptoms, bleeding, pain, bowel changes, bladder symptoms, fever, treatment dates, and questions. This can make clinic visits much more productive.

Ask your team what side effects to expect before they happen. Knowing what is common and what is urgent can reduce panic and help you get help earlier.

Pay attention to nutrition and movement as you are able. Gentle walking, hydration, and enough protein can support recovery, though every plan should be adapted to your energy level and medical situation.

Do not ignore sexual and menopausal symptoms. Vaginal dryness, pain, sudden menopause after ovary removal, and changes in intimacy are common and treatable. Many patients suffer in silence because they are embarrassed to ask.

Emotional distress is common, even in people with early stage disease and good prognosis. Fear of recurrence, body image changes, and uncertainty about the future can be exhausting. Speaking with a counselor, support group, oncology nurse, psycho oncology team, or a trusted cancer specialist can help.

Families should remember that practical support often matters more than perfect words. Rides, meals, note taking during appointments, childcare, or simply sitting with someone after a scan can make a real difference.

When should you talk to a cancer specialist about Endometrial Cancer?

You should speak to a specialist quickly if you have bleeding after menopause, persistent abnormal bleeding before menopause, a biopsy showing hyperplasia with atypia or cancer, or imaging that raises concern for a uterine tumor. Early expert review helps confirm the diagnosis, stage the disease correctly, and avoid delays in treatment (National Cancer Institute, 2025a).

You should also consider a specialist opinion if you have a strong family history of colon or endometrial cancer, possible Lynch syndrome, recurrent disease, or questions about fertility preservation, immunotherapy, or molecular testing.

For many patients, an online consultation can be a practical first step, especially when travel is difficult or when they want a second opinion on biopsy results or treatment choices. What matters most is getting clear, individualized advice from a qualified cancer team.

Frequently Asked Questions about Endometrial Cancer

Can endometrial cancer be cured?

Yes, many cases can be cured, especially when the cancer is found while still confined to the uterus. Cure becomes less likely once the disease has spread, but even then, treatment can still control cancer, ease symptoms, and sometimes produce long remissions (American Cancer Society, 2025).

Does endometrial cancer always cause bleeding?

Not always, but abnormal bleeding is the most common warning sign. Any bleeding after menopause should be checked promptly, even if it happens only once or seems light (National Cancer Institute, 2025a).

Can a normal Pap test rule out endometrial cancer?

No. A Pap test is mainly designed to detect cervical abnormalities, not cancers that begin in the uterine lining. If symptoms suggest endometrial cancer, tissue sampling is usually needed (National Cancer Institute, 2025a).

Will everyone with endometrial cancer need chemotherapy?

No. Many early cancers are treated with surgery alone, with or without radiation. Chemotherapy is more often used when risk is higher, the cancer has spread, or the disease has returned (Concin et al., 2021; National Cancer Institute, 2025a).

Can younger patients preserve fertility?

Sometimes, but only in highly selected cases. Fertility preserving treatment may be considered for carefully chosen patients with very early, low grade endometrioid cancer, and it should be managed by experienced specialists with close monitoring (Rodolakis et al., 2023).

Should all patients have molecular testing?

Molecular classification is increasingly important because it helps estimate risk and can influence treatment choices, especially in advanced disease and in some adjuvant decisions. Whether every patient needs the same testing depends on local practice and the clinical scenario, but the trend is clearly toward broader use (Berek et al., 2023; Galant et al., 2024).

References

• American Cancer Society. 2025. Survival Rates for Endometrial Cancer.

• Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N. 2023. FIGO staging of endometrial cancer: 2023. International Journal of Gynecology and Obstetrics. 162(2):383-394. doi:10.1002/ijgo.14923

• Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, et al. 2021. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 31(1):12-39. doi:10.1136/ijgc-2020-002230

• Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, et al. 2023. Pembrolizumab plus chemotherapy in advanced endometrial cancer. New England Journal of Medicine. 388(23):2159-2170. doi:10.1056/NEJMoa2302312

• Galant N, Krawczyk P, Monist M, Obara A, Gajek L, Grenda A, Nicos M, Kalinka E, Milanowski J. 2024. Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection. International Journal of Molecular Sciences. 25(11):5893. doi:10.3390/ijms25115893

• International Agency for Research on Cancer. 2024. Corpus Uteri Fact Sheet. Global Cancer Observatory.

• Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, et al. 2023. Dostarlimab for primary advanced or recurrent endometrial cancer. New England Journal of Medicine. 388(23):2145-2158. doi:10.1056/NEJMoa2216334

• National Cancer Institute. 2025a. Endometrial Cancer Treatment (PDQ)-Health Professional Version.

• National Cancer Institute. 2025b. Endometrial Cancer Screening (PDQ)-Patient Version.

• Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, Grynberg M, Pakiz M, Pavlakis K, Vermeulen N, Zannoni G, Zapardiel I, Macklon KLT. 2023. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Human Reproduction Open. 2023(1):hoac057. doi:10.1093/hropen/hoac057